再生醫學/細胞治療
NEW

醫事司劉越萍：再生醫療法明年增修子法規 強化人員訓練、廣告、倫理  
生技醫藥
NEW

擊敗嬌生？GSK三期多發性骨髓瘤ADC捲土重來

新聞集錦
NEW

MSD斥5.88億美元 取中國禮新PD-1/VEGF雙靶點抗體藥；Gilead關閉西雅圖辦事處 明年年中再關Kite費城工廠

GBI International
GBIHighlights

Sartorius experts highlighted the key specifications of the new PIC/S GMP Annex 1 regulation

2024-02-28/GlobalBio & Investment
#BiotechInsightsExcitingupdatesfromSartoriusandAdimmuneCorp(4142)'scorporateseminar!Sartoriusexperts,Tse-WeiChenandRZLin,highlightedthelatesttrendsincellculturedevelopmentandthekeyspecificationsof...
GBI International
GBIHighlights

AnHorn partnered with European startups to explore new treatment targets for prostate cancer

2024-02-28/GlobalBio & Investment
#InnovativeCollaborationAnHornMedicines,anAI-drivendrugdiscoverycompanyfocusedonproteindegradation,haspartneredwithEuropeanstartupstoexplorenewtreatmenttargetsforprostatecancer.On20February2024,Anhorn...
GBI International
GBIHighlights

PharmaEssentia and Oneness Biotech Co Ltd have been honored in Sustainability Yearbook 2024

2024-02-28/GlobalBio & Investment
#ESGExcellenceExcitingnews!PharmaEssentia(TPE:6446)andOnenessBiotechCoLtd(TPE:4743)havebeenhonoredintheprestigiousSustainabilityYearbook2024byS&PGlobalRatings.PharmaEssentiamarksahistoricmomentast...
GBI International
GBIHighlights

How does medical technology revolutionize commercial health insurance?

2024-02-28/GlobalBio & Investment
#MedicalInsuranceDidyouknowthattheaveragepersoninTaiwanhasthreeinsurancepolicies?Withtheriseofemergingmedicaltechnology,commercialhealthinsuranceisbeingrevolutionized.In2023,theBio-TaiwanCommittee(#BT...
GBI International
GBIHighlights

Leadgene Biomedical, Inc.'s LEADGENE® IS ELISA Kit has been approved by Taiwan's FDA...

2024-02-28/GlobalBio & Investment
#TFDAApprovalExcitingnews!LeadgeneBiomedical,Inc.'sLEADGENE®IndoxylSulfate(IS)ELISAKit,aCE-markedprotein-boundtoxindiagnosiskit,hasbeenapprovedbyTaiwan'sFDAasaClassIIIinvitrodiagnosticdevi...
GBI International
GBIHighlights

Nine biopharma companies have announced record-high revenues for January

2024-02-28/GlobalBio & Investment
#BiotechGrowthExcitingnewsfromthe#biopharmasector!Ninebiopharmacompanieshaveannouncedrecord-highrevenuesforJanuary,indicatingaprosperousstarttotheyear.Amongthem,AnxoPharmaceuticalTaiwanCo.Ltd(6677.TWO...
GBI International
GBIHighlights

FDA approves Onivyde® as a first-line therapy for metastatic pancreatic adenocarcinoma

2024-02-28/GlobalBio & Investment
**#FDAApproval**ExcitingnewsforPharmaEngineInc(4162.TWO)!FDAapproves#Onivyde®asafirst-linetherapyformetastaticpancreaticadenocarcinoma,markingapotentialnewstandardofcare.PharmaEngine'scollabor...
GBI International
GBIHighlights

The potential of next-generation microbiome therapy in clinical applications (8th AMC)

2024-02-28/GlobalBio & Investment
*#MicrobiomeTherapy**Canthegutmicrobiotarevolutionizecancertreatment?Insightsfromthe8thAsiaMicrobiomeConference(#AMC),heldbyIBCAcademiaSinica,NationalTaiwanUniversityHospital,and圖爾思生物科技BIOTOOLSCO.,LTD...
GBI International
GBIHighlights

Chang Gung Medical Foundation teams up with Gilead Sciences to accelerate early-stage clinical trial

2024-02-28/GlobalBio & Investment
**#ClinicalTrials**ChangGungMedicalFoundationteamsupwithGileadSciencestoaccelerateearly-stageclinicaltrials,focusingon#oncology.Thecollaborationaimstoadvanceclinicaltrialsintumorresearch,preclinicalco...
GBI International
GBIHighlights

GBI Spotlight: Dr. Han-Chung Wu

2024-02-28/GlobalBio & Investment
#GBISpotlight:Dr.Han-ChungWu(吳漢忠)MeetDr.Han-ChungWu,themanbehindthedevelopmentofprecisiontherapythroughinnovativephagedisplaytechnology.AstheDirectorofBioTrecatNBRP,AcademiaSinica,heisawell-knownfigur...
GBI International
GBIHighlights

Meet David Lee, the visionary founder and CEO of Singular Wings Medical

2024-02-28/GlobalBio & Investment
**#Meet#StartupCEOs**MeetDavidLee(李維中),thevisionaryfounderandCEOofSingularWingsMedical.Fromtheelectronicsindustrytoentrepreneurship,hemerges#healthcarewith#electronics,craftinginnovativesolutionsforme...
GBI International
GBIHighlights

Merck's Keytruda Leads 2023 Sales!

2024-02-28/GlobalBio & Investment
**Merck'sKeytrudaLeads2023Sales!**Merck'sKeytrudaemergesasthetop-sellingdrugof2023,amassinganimpressive$25billioninsales.MerckCFOCarolineLitchfieldattributesKeytruda'ssurgein2023torecentap...

TOP
  • Global Bio and Investment Monthly
  • 讀者服務電話：+886 2 2726 1065時間：週一 ~ 週五 09:00 ~ 18:00
  • 服務信箱：[email protected]
  • 地址：110臺北市信義區信義路六段29號2樓之一, Taiwan

我們的服務